HC Wainwright Issues Pessimistic Estimate for PVLA Earnings

Palvella Therapeutics, Inc. (NASDAQ:PVLA) – Investment analysts at HC Wainwright reduced their Q2 2026 earnings per share estimates for shares of Palvella Therapeutics in a note issued to investors on Friday, May 8th. HC Wainwright analyst A. Fein now anticipates that the company will post earnings of ($1.42) per share for the quarter, down from their prior estimate of ($1.02). HC Wainwright has a “Buy” rating and a $270.00 price objective on the stock. The consensus estimate for Palvella Therapeutics’ current full-year earnings is ($4.88) per share. HC Wainwright also issued estimates for Palvella Therapeutics’ Q3 2026 earnings at ($1.69) EPS, Q4 2026 earnings at ($1.89) EPS, FY2026 earnings at ($6.21) EPS, FY2027 earnings at ($6.28) EPS, FY2028 earnings at $0.40 EPS, FY2029 earnings at $7.81 EPS and FY2030 earnings at $21.72 EPS.

Other equities analysts have also recently issued research reports about the company. BTIG Research boosted their price objective on Palvella Therapeutics from $192.00 to $215.00 and gave the company a “buy” rating in a report on Wednesday, February 25th. Stephens started coverage on Palvella Therapeutics in a report on Tuesday. They issued an “overweight” rating for the company. Chardan Capital boosted their price objective on Palvella Therapeutics from $210.00 to $240.00 and gave the company a “buy” rating in a report on Tuesday, March 31st. Stifel Nicolaus set a $250.00 price objective on Palvella Therapeutics in a report on Tuesday, February 24th. Finally, Truist Financial set a $210.00 price objective on Palvella Therapeutics in a report on Tuesday, February 24th. One analyst has rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, Palvella Therapeutics has an average rating of “Moderate Buy” and an average price target of $198.07.

Palvella Therapeutics Stock Performance

Shares of PVLA opened at $122.09 on Tuesday. The stock has a 50-day moving average of $125.59 and a two-hundred day moving average of $103.07. Palvella Therapeutics has a one year low of $20.20 and a one year high of $151.18. The stock has a market cap of $1.75 billion, a P/E ratio of -29.28 and a beta of -0.13.

Palvella Therapeutics (NASDAQ:PVLA) last issued its quarterly earnings results on Thursday, May 7th. The company reported ($1.20) EPS for the quarter, missing analysts’ consensus estimates of ($0.90) by ($0.30).

Insider Activity at Palvella Therapeutics

In related news, COO Kathleen Goin sold 4,302 shares of Palvella Therapeutics stock in a transaction dated Wednesday, March 18th. The stock was sold at an average price of $117.99, for a total value of $507,592.98. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director George M. Jenkins purchased 4,000 shares of the business’s stock in a transaction that occurred on Friday, February 27th. The stock was acquired at an average price of $125.00 per share, with a total value of $500,000.00. Following the purchase, the director owned 187,171 shares in the company, valued at $23,396,375. This represents a 2.18% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. 20.50% of the stock is owned by company insiders.

Hedge Funds Weigh In On Palvella Therapeutics

Institutional investors and hedge funds have recently modified their holdings of the business. Group One Trading LLC increased its stake in Palvella Therapeutics by 151.5% during the 4th quarter. Group One Trading LLC now owns 332 shares of the company’s stock worth $35,000 after buying an additional 200 shares in the last quarter. KBC Group NV purchased a new stake in Palvella Therapeutics during the 1st quarter worth approximately $28,000. Price T Rowe Associates Inc. MD increased its stake in Palvella Therapeutics by 11.8% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 4,090 shares of the company’s stock worth $429,000 after buying an additional 433 shares in the last quarter. Archer Investment Corp purchased a new stake in Palvella Therapeutics during the 3rd quarter worth approximately $28,000. Finally, Bank of America Corp DE increased its stake in Palvella Therapeutics by 12.3% during the 3rd quarter. Bank of America Corp DE now owns 4,689 shares of the company’s stock worth $294,000 after buying an additional 515 shares in the last quarter. Hedge funds and other institutional investors own 40.11% of the company’s stock.

About Palvella Therapeutics

Palvella Therapeutics, Inc (NASDAQ: PVLA) is a clinical?stage biopharmaceutical company devoted to the discovery and development of innovative therapies for immunological and inflammatory diseases. The company employs a proprietary small?molecule and biologics platform to identify and modulate key molecular pathways that drive neutrophil? and complement?mediated inflammation, aiming to deliver targeted treatment options for patients with significant unmet medical needs.

Palvella’s pipeline comprises several preclinical assets designed to address both prevalent chronic inflammatory conditions and rare autoinflammatory syndromes.